These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25893294)

  • 21. Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer.
    Verma SK
    Curr Top Med Chem; 2015; 15(8):714-9. PubMed ID: 25732793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
    Knutson SK; Kawano S; Minoshima Y; Warholic NM; Huang KC; Xiao Y; Kadowaki T; Uesugi M; Kuznetsov G; Kumar N; Wigle TJ; Klaus CR; Allain CJ; Raimondi A; Waters NJ; Smith JJ; Porter-Scott M; Chesworth R; Moyer MP; Copeland RA; Richon VM; Uenaka T; Pollock RM; Kuntz KW; Yokoi A; Keilhack H
    Mol Cancer Ther; 2014 Apr; 13(4):842-54. PubMed ID: 24563539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule inhibitors of EZH2: the emerging translational landscape.
    Keilhack H; Smith JJ
    Epigenomics; 2015; 7(3):337-41. PubMed ID: 26077423
    [No Abstract]   [Full Text] [Related]  

  • 24. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
    Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
    J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SAH derived potent and selective EZH2 inhibitors.
    Kung PP; Huang B; Zehnder L; Tatlock J; Bingham P; Krivacic C; Gajiwala K; Diehl W; Yu X; Maegley KA
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1532-7. PubMed ID: 25746813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of enhancer of zests homolog 2 in lymphoma.
    Guo SQ; Zhang YZ
    Chin Med J (Engl); 2012 Oct; 125(20):3735-9. PubMed ID: 23075734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
    Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
    Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
    Wu D; Zeng X; Zhao Y; Qin M; Gong P
    Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
    Cohen AS; Yap DB; Lewis ME; Chijiwa C; Ramos-Arroyo MA; Tkachenko N; Milano V; Fradin M; McKinnon ML; Townsend KN; Xu J; Van Allen MI; Ross CJ; Dobyns WB; Weaver DD; Gibson WT
    Hum Mutat; 2016 Mar; 37(3):301-7. PubMed ID: 26694085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.
    Wigle TJ; Knutson SK; Jin L; Kuntz KW; Pollock RM; Richon VM; Copeland RA; Scott MP
    FEBS Lett; 2011 Oct; 585(19):3011-4. PubMed ID: 21856302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reaction coupling between wild-type and disease-associated mutant EZH2.
    Swalm BM; Knutson SK; Warholic NM; Jin L; Kuntz KW; Keilhack H; Smith JJ; Pollock RM; Moyer MP; Scott MP; Copeland RA; Wigle TJ
    ACS Chem Biol; 2014 Nov; 9(11):2459-64. PubMed ID: 25154026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
    Li B; Chng WJ
    J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
    Barsotti AM; Ryskin M; Rollins RA
    Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
    [No Abstract]   [Full Text] [Related]  

  • 36. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
    Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
    Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
    Katoh M
    Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
    Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
    Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
    Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
    Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.